DiaSorin stock: management reaffirmed its 2026 outlook in July earnings call

DiaSorin management reaffirmed its 2026 outlook during a July earnings call. The discussion covered first-half performance and a return to growth in the second quarter at constant exchange rates.

DiaSorin management reaffirmed its full-year 2026 outlook during the company’s July 31, 2026, first-half results conference call. The discussion also covered the company’s operating performance and product development. Yahoo Finance published the transcript.

Second-quarter performance

During the call, management said DiaSorin’s second quarter returned to growth at constant exchange rates after a weaker first quarter. The company also discussed progress in its immunodiagnostics, molecular diagnostics and life-science technology businesses. The transcript records comments from CEO Carlo Rosa and CFO Alberto Donati.